A Single-arm, Open, Phase II Study of Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Latest Information Update: 14 Apr 2023
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 11 Apr 2023 Planned End Date changed from 15 May 2023 to 15 May 2024.
- 11 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 04 Sep 2022 Planned End Date changed from 15 Jun 2022 to 15 May 2023.